{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T11:40:58Z","timestamp":1782906058081,"version":"3.54.5"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,7]],"date-time":"2023-01-07T00:00:00Z","timestamp":1673049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,7]],"date-time":"2023-01-07T00:00:00Z","timestamp":1673049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003252","name":"Lunds Universitet","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003252","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100009780","name":"Region Sk\u00e5ne","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009780","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100006738","name":"Medicinska Fakulteten, Lunds Universitet","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006738","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003793","name":"Hj\u00e4rt-Lungfonden","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003793","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003173","name":"Crafoordska Stiftelsen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003173","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100008986","name":"Sydv\u00e4stra Sk\u00e5nes Diabetesf\u00f6rening","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100008986","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100006189","name":"Direkt\u00f6r\u00a0Albert P\u00e5hlssons Stiftelse","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006189","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100009748","name":"Ernhold Lundstr\u00f6ms stiftelse","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009748","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004063","name":"Knut och Alice Wallenbergs Stiftelse","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004063","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100011747","name":"Novo Nordisk Foundation Center for Basic Metabolic Research","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100011747","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001729","name":"Stiftelsen f\u00f6r\u00a0Strategisk Forskning","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001729","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100011077","name":"Sk\u00e5nes universitetssjukhus","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100011077","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100009761","name":"Hulda och E Conrad Mossfelts Stiftelse f\u00f6r Vetenskaplig Forskning Inom Hj\u00e4rt- och K\u00e4rlsjukdomarnas Omr\u00e5de","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009761","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100006129","name":"Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006129","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004158","name":"Marcus Wallenbergs Stiftelse f\u00f6r Internationellt Vetenskapligt Samarbete","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004158","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003252","name":"Lund University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003252","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Concerns have been raised regarding a potentially increased risk of cancer associated with treatment with glucagon-like peptide-1 (GLP-1) receptor agonists. Here, we explored whether fasting and oral glucose tolerance test post-challenge glucose-dependent insulinotropic peptide (GIP) and GLP-1 levels were associated with incident first cancer. Within the cardiovascular re-examination arm of the population-based Malm\u00f6 Diet Cancer study (n\u2009=\u20093734), 685 participants with a previous cancer diagnosis were excluded, resulting in 3049 participants (mean age 72.2\u2009\u00b1\u20095.6\u00a0years, 59.5% women), of whom 485 were diagnosed with incident first cancer (median follow-up time 9.9\u00a0years). Multivariable Cox-regression and competing risk regression (death as competing risk) were used to explore associations between incretin levels and incident first cancer. Higher levels of fasting GLP-1 (462 incident first cancer cases\/2417 controls) showed lower risk of incident first cancer in competing risk regression (sub-hazard ratio 0.90; 95% confidence interval 0.82\u20130.99; p\u2009=\u20090.022). No association was seen for fasting GIP, post-challenge GIP, or post-challenge GLP-1 and incident first cancer. In this prospective study, none of the fasting and post-challenge levels of GIP and GLP-1 were associated with higher risk of incident first cancer; by contrast, higher levels of fasting GLP-1 were associated with lower risk of incident first cancer.\n<\/jats:p>","DOI":"10.1038\/s41598-023-27509-3","type":"journal-article","created":{"date-parts":[[2023,1,7]],"date-time":"2023-01-07T15:24:34Z","timestamp":1673105074000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Endogenous incretin levels and risk of first incident cancer: a prospective cohort study"],"prefix":"10.1038","volume":"13","author":[{"given":"Amra","family":"Juji\u0107","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Godina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattias","family":"Belting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olle","family":"Melander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Juul Holst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Ahlqvist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria F.","family":"Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter M.","family":"Nilsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Jernstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Magnusson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,7]]},"reference":[{"key":"27509_CR1","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1124\/pr.55.1.6","volume":"55","author":"KE Mayo","year":"2003","unstructured":"Mayo, K. E. et al. International Union of Pharmacology. XXXV. The glucagon receptor family. Pharmacol. Rev. 55, 167\u2013194. https:\/\/doi.org\/10.1124\/pr.55.1.6 (2003).","journal-title":"Pharmacol. Rev."},{"key":"27509_CR2","doi-asserted-by":"publisher","first-page":"212283","DOI":"10.7573\/dic.212283","volume":"4","author":"L Prasad-Reddy","year":"2015","unstructured":"Prasad-Reddy, L. & Isaacs, D. A clinical review of GLP-1 receptor agonists: Efficacy and safety in diabetes and beyond. Drugs Context 4, 212283. https:\/\/doi.org\/10.7573\/dic.212283 (2015).","journal-title":"Drugs Context"},{"key":"27509_CR3","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.tem.2019.07.004","volume":"30","author":"I Caruso","year":"2019","unstructured":"Caruso, I., Cignarelli, A. & Giorgino, F. Heterogeneity and similarities in GLP-1 receptor agonist cardiovascular outcomes trials. Trends Endocrinol. Metab. 30, 578\u2013589. https:\/\/doi.org\/10.1016\/j.tem.2019.07.004 (2019).","journal-title":"Trends Endocrinol. Metab."},{"key":"27509_CR4","doi-asserted-by":"publisher","first-page":"3316","DOI":"10.2337\/db13-0822","volume":"62","author":"DJ Drucker","year":"2013","unstructured":"Drucker, D. J. Incretin action in the pancreas: Potential promise, possible perils, and pathological pitfalls. Diabetes 62, 3316\u20133323. https:\/\/doi.org\/10.2337\/db13-0822 (2013).","journal-title":"Diabetes"},{"key":"27509_CR5","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.cmet.2006.01.004","volume":"3","author":"DJ Drucker","year":"2006","unstructured":"Drucker, D. J. The biology of incretin hormones. Cell Metab. 3, 153\u2013165. https:\/\/doi.org\/10.1016\/j.cmet.2006.01.004 (2006).","journal-title":"Cell Metab."},{"key":"27509_CR6","doi-asserted-by":"publisher","first-page":"925377","DOI":"10.3389\/fphar.2022.925377","volume":"13","author":"Z Yang","year":"2022","unstructured":"Yang, Z. et al. GLP-1 receptor agonist-associated tumor adverse events: A real-world study from 2004 to 2021 based on FAERS. Front. Pharmacol. 13, 925377. https:\/\/doi.org\/10.3389\/fphar.2022.925377 (2022).","journal-title":"Front. Pharmacol."},{"key":"27509_CR7","doi-asserted-by":"publisher","first-page":"286","DOI":"10.2337\/dc17-0280","volume":"41","author":"M Boniol","year":"2018","unstructured":"Boniol, M. et al. Incretin-based therapies and the short-term risk of pancreatic cancer: Results from two retrospective cohort studies. Diabetes Care 41, 286\u2013292. https:\/\/doi.org\/10.2337\/dc17-0280 (2018).","journal-title":"Diabetes Care"},{"key":"27509_CR8","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1053\/j.gastro.2011.02.018","volume":"141","author":"M Elashoff","year":"2011","unstructured":"Elashoff, M., Matveyenko, A. V., Gier, B., Elashoff, R. & Butler, P. C. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 141, 150\u2013156. https:\/\/doi.org\/10.1053\/j.gastro.2011.02.018 (2011).","journal-title":"Gastroenterology"},{"key":"27509_CR9","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1053\/j.gastro.2011.05.019","volume":"141","author":"J Spranger","year":"2011","unstructured":"Spranger, J., Gundert-Remy, U. & Stammschulte, T. GLP-1-based therapies: The dilemma of uncertainty. Gastroenterology 141, 20\u201323. https:\/\/doi.org\/10.1053\/j.gastro.2011.05.019 (2011).","journal-title":"Gastroenterology"},{"key":"27509_CR10","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/dom.12230","volume":"16","author":"D Funch","year":"2014","unstructured":"Funch, D., Gydesen, H., Torn\u00f8e, K., Major-Pedersen, A. & Chan, K. A. A prospective, claims-based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugs. Diabetes Obes. Metab. 16, 273\u2013275. https:\/\/doi.org\/10.1111\/dom.12230 (2014).","journal-title":"Diabetes Obes. Metab."},{"key":"27509_CR11","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1089\/dia.2012.0075","volume":"14","author":"JA Romley","year":"2012","unstructured":"Romley, J. A., Goldman, D. P., Solomon, M. & McFadden, D. Peters AL Exenatide therapy and the risk of pancreatitis and pancreatic cancer in a privately insured population. Diabetes Technol. Therap. 14, 904\u2013911. https:\/\/doi.org\/10.1089\/dia.2012.0075 (2012).","journal-title":"Diabetes Technol. Therap."},{"key":"27509_CR12","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1093\/jnci\/89.18.1360","volume":"89","author":"L Wideroff","year":"1997","unstructured":"Wideroff, L. et al. Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J. Natl. Cancer Inst. 89, 1360\u20131365. https:\/\/doi.org\/10.1093\/jnci\/89.18.1360 (1997).","journal-title":"J. Natl. Cancer Inst."},{"key":"27509_CR13","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s10549-011-1585-0","volume":"132","author":"H Ligumsky","year":"2012","unstructured":"Ligumsky, H. et al. The peptide-hormone glucagon-like peptide-1 activates cAMP and inhibits growth of breast cancer cells. Breast Cancer Res. Treat. 132, 449\u2013461. https:\/\/doi.org\/10.1007\/s10549-011-1585-0 (2012).","journal-title":"Breast Cancer Res. Treat."},{"key":"27509_CR14","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"27509_CR15","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1186\/s12916-018-1215-3","volume":"16","author":"H Zhu","year":"2018","unstructured":"Zhu, H., Li, T., Du, Y. & Li, M. Pancreatic cancer: Challenges and opportunities. BMC Med. 16, 214. https:\/\/doi.org\/10.1186\/s12916-018-1215-3 (2018).","journal-title":"BMC Med."},{"key":"27509_CR16","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.atherosclerosis.2015.01.030","volume":"239","author":"M Rosvall","year":"2015","unstructured":"Rosvall, M. et al. Risk factors for the progression of carotid intima-media thickness over a 16-year follow-up period: The Malmo diet and cancer study. Atherosclerosis 239, 615\u2013621. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2015.01.030 (2015).","journal-title":"Atherosclerosis"},{"key":"27509_CR17","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/BF00280883","volume":"28","author":"DR Matthews","year":"1985","unstructured":"Matthews, D. R. et al. Homeostasis model assessment: Insulin resistance and \u03b2-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28, 412\u2013419. https:\/\/doi.org\/10.1007\/BF00280883 (1985).","journal-title":"Diabetologia"},{"key":"27509_CR18","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1002\/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S","volume":"15","author":"KG Alberti","year":"1998","unstructured":"Alberti, K. G. & Zimmet, P. Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet. Med. 15, 539\u2013553. https:\/\/doi.org\/10.1002\/(SICI)1096-9136(199807)15:7%3c539::AID-DIA668%3e3.0.CO;2-S (1998).","journal-title":"Diabet. Med."},{"key":"27509_CR19","doi-asserted-by":"publisher","first-page":"224","DOI":"10.2337\/dc20-1318","volume":"44","author":"A Juji\u0107","year":"2020","unstructured":"Juji\u0107, A. et al. Glucose-dependent insulinotropic peptide in the high-normal range is associated with increased carotid intima-media thickness. Diabetes Care 44, 224\u2013230. https:\/\/doi.org\/10.2337\/dc20-1318 (2020).","journal-title":"Diabetes Care"},{"key":"27509_CR20","unstructured":"Gastrointestinal \u2022 Endocrine and metabolic diseases. Curr. Opin. Pharmacol. 13(6), 843\u20131002 (2013)."},{"key":"27509_CR21","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1016\/j.coph.2013.08.013","volume":"13","author":"M Ezcurra","year":"2013","unstructured":"Ezcurra, M., Reimann, F., Gribble, F. M. & Emery, E. Molecular mechanisms of incretin hormone secretion. Curr. Opin. Pharmacol. 13, 922\u2013927. https:\/\/doi.org\/10.1016\/j.coph.2013.08.013 (2013).","journal-title":"Curr. Opin. Pharmacol."},{"key":"27509_CR22","doi-asserted-by":"publisher","first-page":"6354","DOI":"10.1158\/0008-5472.Can-18-0687","volume":"78","author":"JW Russo","year":"2018","unstructured":"Russo, J. W. et al. Downregulation of dipeptidyl peptidase 4 accelerates progression to castration-resistant prostate cancer. Cancer Res. 78, 6354\u20136362. https:\/\/doi.org\/10.1158\/0008-5472.Can-18-0687 (2018).","journal-title":"Cancer Res."},{"key":"27509_CR23","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1055\/a-1345-7890","volume":"71","author":"A Shadboorestan","year":"2021","unstructured":"Shadboorestan, A. et al. Growth promotion and increased ATP-Binding cassette transporters expression by liraglutide in triple negative breast cancer cell line MDA-MB-231. Drug Res. (Stuttg.) 71, 307\u2013311 (2021).","journal-title":"Drug Res. (Stuttg.)"},{"key":"27509_CR24","doi-asserted-by":"publisher","DOI":"10.2337\/dc22-1148","author":"J Bezin","year":"2022","unstructured":"Bezin, J. et al. GLP-1 Receptor agonists and the risk of thyroid cancer. Diabetes Care. https:\/\/doi.org\/10.2337\/dc22-1148 (2022).","journal-title":"Diabetes Care."},{"key":"27509_CR25","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1111\/dme.14287","volume":"37","author":"J Rouette","year":"2020","unstructured":"Rouette, J. et al. Incretin-based drugs and risk of lung cancer among individuals with type 2 diabetes. Diabet. Med. 37, 868\u2013875. https:\/\/doi.org\/10.1111\/dme.14287 (2020).","journal-title":"Diabet. Med."},{"key":"27509_CR26","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1001\/jamainternmed.2022.0338","volume":"182","author":"L He","year":"2022","unstructured":"He, L. et al. Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: A systematic review and meta-analysis of randomized clinical trials. JAMA Intern. Med. 182, 513\u2013519. https:\/\/doi.org\/10.1001\/jamainternmed.2022.0338 (2022).","journal-title":"JAMA Intern. Med."},{"key":"27509_CR27","doi-asserted-by":"publisher","first-page":"1534365","DOI":"10.1155\/2019\/1534365","volume":"2019","author":"Y Liu","year":"2019","unstructured":"Liu, Y., Zhang, X., Chai, S., Zhao, X. & Ji, L. Risk of malignant neoplasia with glucagon-like peptide-1 receptor agonist treatment in patients with type 2 diabetes: A meta-analysis. J. Diabetes Res. 2019, 1534365. https:\/\/doi.org\/10.1155\/2019\/1534365 (2019).","journal-title":"J. Diabetes Res."},{"key":"27509_CR28","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/s0140-6736(08)60269-x","volume":"371","author":"AG Renehan","year":"2008","unstructured":"Renehan, A. G., Tyson, M., Egger, M., Heller, R. F. & Zwahlen, M. Body-mass index and incidence of cancer: A systematic review and meta-analysis of prospective observational studies. Lancet 371, 569\u2013578. https:\/\/doi.org\/10.1016\/s0140-6736(08)60269-x (2008).","journal-title":"Lancet"},{"key":"27509_CR29","doi-asserted-by":"publisher","first-page":"5149","DOI":"10.1210\/en.2003-0323","volume":"144","author":"L Farilla","year":"2003","unstructured":"Farilla, L. et al. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 144, 5149\u20135158. https:\/\/doi.org\/10.1210\/en.2003-0323 (2003).","journal-title":"Endocrinology"},{"key":"27509_CR30","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.2337\/diabetes.48.12.2270","volume":"48","author":"G Xu","year":"1999","unstructured":"Xu, G., Stoffers, D. A., Habener, J. F. & Bonner-Weir, S. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 48, 2270\u20132276. https:\/\/doi.org\/10.2337\/diabetes.48.12.2270 (1999).","journal-title":"Diabetes"},{"key":"27509_CR31","doi-asserted-by":"publisher","first-page":"4600","DOI":"10.1210\/endo.141.12.7806","volume":"141","author":"R Perfetti","year":"2000","unstructured":"Perfetti, R., Zhou, J., Doyle, M. I. E. & Egan, J. M. Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. Endocrinology 141, 4600\u20134605. https:\/\/doi.org\/10.1210\/endo.141.12.7806 (2000).","journal-title":"Endocrinology"},{"key":"27509_CR32","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1126\/scitranslmed.3003110","volume":"3","author":"SS Hori","year":"2011","unstructured":"Hori, S. S. & Gambhir, S. S. Mathematical model identifies blood biomarker based early cancer detection strategies and limitations. Sci. Transl. Med. 3, 109\u2013116. https:\/\/doi.org\/10.1126\/scitranslmed.3003110 (2011).","journal-title":"Sci. Transl. Med."},{"key":"27509_CR33","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.2337\/dc10-0666","volume":"33","author":"E Giovannucci","year":"2010","unstructured":"Giovannucci, E. et al. Diabetes and cancer: A consensus report. Diabetes Care 33, 1674\u20131685. https:\/\/doi.org\/10.2337\/dc10-0666 (2010).","journal-title":"Diabetes Care"},{"key":"27509_CR34","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s10654-011-9647-5","volume":"27","author":"G Edgren","year":"2012","unstructured":"Edgren, G., Liang, L., Adami, H.-O. & Chang, E. T. Enigmatic sex disparities in cancer incidence. Eur. J. Epidemiol. 27, 187\u2013196. https:\/\/doi.org\/10.1007\/s10654-011-9647-5 (2012).","journal-title":"Eur. J. Epidemiol."},{"key":"27509_CR35","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1158\/1055-9965.Epi-08-1118","volume":"18","author":"MB Cook","year":"2009","unstructured":"Cook, M. B. et al. Sex disparities in cancer incidence by period and age. Cancer Epidemiol. Biomark. Prev. 18, 1174\u20131182. https:\/\/doi.org\/10.1158\/1055-9965.Epi-08-1118 (2009).","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"27509_CR36","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21332","volume":"66","author":"RL Siegel","year":"2016","unstructured":"Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2016. CA Cancer J. Clin. 66, 7\u201330. https:\/\/doi.org\/10.3322\/caac.21332 (2016).","journal-title":"CA Cancer J. Clin."},{"key":"27509_CR37","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1186\/s12885-021-08481-5","volume":"21","author":"Q Shen","year":"2021","unstructured":"Shen, Q., Schelin, M. E. C., Fang, F. & J\u00f6ud, A. Diagnostic codes of cancer in Sk\u00e5ne healthcare register: A validation study using individual-level data in southern Sweden. BMC Cancer 21, 759. https:\/\/doi.org\/10.1186\/s12885-021-08481-5 (2021).","journal-title":"BMC Cancer"},{"key":"27509_CR38","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.ejca.2014.10.025","volume":"51","author":"K Tomic","year":"2015","unstructured":"Tomic, K. et al. Evaluation of data quality in the National Prostate Cancer Register of Sweden. Eur. J. Cancer 51, 101\u2013111. https:\/\/doi.org\/10.1016\/j.ejca.2014.10.025 (2015).","journal-title":"Eur. J. Cancer"},{"key":"27509_CR39","unstructured":"Socialstyrelsen. https:\/\/www.socialstyrelsen.se\/en\/statistics-and-data\/registers\/alla-register\/swedish-cancer-register\/ (Assessed 26 November 2021) (2019)."},{"key":"27509_CR40","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.2337\/db14-1751","volume":"64","author":"K F\u00e6rch","year":"2015","unstructured":"F\u00e6rch, K. et al. GLP-1 response to oral glucose is reduced in prediabetes, screen-detected type 2 diabetes, and obesity and influenced by sex: The ADDITION-PRO study. Diabetes 64, 2513\u20132525. https:\/\/doi.org\/10.2337\/db14-1751 (2015).","journal-title":"Diabetes"},{"key":"27509_CR41","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.mce.2008.08.012","volume":"297","author":"JJ Holst","year":"2009","unstructured":"Holst, J. J., Vilsb\u00f8ll, T. & Deacon, C. F. The incretin system and its role in type 2 diabetes mellitus. Mol. Cell. Endocrinol. 297, 127\u2013136. https:\/\/doi.org\/10.1016\/j.mce.2008.08.012 (2009).","journal-title":"Mol. Cell. Endocrinol."},{"key":"27509_CR42","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.jand.2013.09.018","volume":"114","author":"LG Sylvia","year":"2014","unstructured":"Sylvia, L. G., Bernstein, E. E., Hubbard, J. L., Keating, L. & Anderson, E. J. Practical guide to measuring physical activity. J. Acad. Nutr. Diet 114, 199\u2013208. https:\/\/doi.org\/10.1016\/j.jand.2013.09.018 (2014).","journal-title":"J. Acad. Nutr. Diet"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-27509-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-27509-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-27509-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T15:09:27Z","timestamp":1673363367000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-27509-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,7]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["27509"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-27509-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,7]]},"assertion":[{"value":"13 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JJH and EA have received funding from the Novo Nordisk Foundation. The remaining authors have no relevant financial or non-financial interests to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"382"}}